Review of GLP1 receptor antagonists @ יואל קסלר
In this post Review of GLP1 receptor antagonists @ יואל קסלר we present a link to a newly published short review of GLP 1 receptor antagonists and their use in the management of diabetes mellitus. The article was published in the Cleveland Clinic Journal of Medicine by Noura Nachawi, MD, Pratibha PR Rao, MD, MPH and Vinni Makin, MBBS, MD, FACE and can can be read in full there.
The main points of the article focus on:
- Long-acting GLP-1 receptor agonists control glycemia a little better than short-acting agents and better than insulin, lowering hemoglobin A1c by about 1%.
- Large, randomized clinical trials of GLP-1 receptor agonists have had positive or at worst neutral results in terms of preventing major adverse cardiovascular events in patients with type 2 diabetes who either had cardiovascular disease at baseline or were at high risk of it.
- GLP-1 receptor agonists have a protective effect on the kidneys, reducing the risk of macroalbuminuria, but perhaps do not help preserve the glomerular filtration rate as much as sodium-glucose transporter-2 inhibitors.
- GLP-1 receptor agonists are recommended as either first-line or second-line therapy regardless of baseline hemoglobin A1c in patients who have established atherosclerotic cardiovascular disease, high risk of atherosclerotic cardiovascular disease, chronic kidney disease, or heart failure.
THE BOTTOM LINE
GLP-1 receptor agonists are recommended as either first-line or second-line therapy regardless of baseline hemoglobin A1c in patients who have established atherosclerotic cardiovascular disease, high risk of atherosclerotic cardiovascular disease, chronic kidney disease, or heart failure. Some agents are also approved for weight management in patients with a body mass index of 27 kg/m2or higher with weight-related comorbidities or a body mass index of 30 kg/m2 or higher.
For more interesting articles like this check out are blog.
